References
- Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–513.
- Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
- Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
- Mauskopf J, Samuel M, McBride D, et al. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014;32(4):395–409.
- Bewley A, Barker J, Mughal F, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. Cogent Med. 2018;5(1):1495593.
- Ramaekers BLT, Wolff RF, Pouwels X, et al. Ixekizumab for treating moderate-to-severe plaque psoriasis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(8):917–927.
- Armstrong A, Jarvis S, Boehncke WH, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200–2207.
- Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302.
- National Institute for Health and Care Excellence. Brodalumab for treating moderate to severe plaque psoriasis: technology appraisal guidance [TA511]. National Institute for Health and Care Excellence, London, UK; 2018.
- British National Formulary. National Institute for Health and Care Excellence; 2019 [cited 2021 Mar 22]. Available from: https://www.nice.org.uk/about/what-we-do/evidence-services/british-national-formulary.
- NHS Improvement. Reference costs 2017/18: highlights, analysis and introduction to the data. London (UK): NHS Improvement; 2018.
- Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807–816.
- National Institute for Health Care Excellence. Guide to the methods of technology appraisal 2013. London (UK): National Institute for Health and Care Excellence; 2013.